Aribio Announces AR1001 Phase 3 Clinical Trial Status at CTAD... Reveals Potential Blood Biomarker Evaluation

Aribio announced on the 29th that it will participate in the 17th Clinical Trials on Alzheimer's Disease (CTAD) held in Madrid, Spain, from today until the 1st of next month. The company plans to present a total of four research results, including potential blood assessments from the Phase 3 clinical trial of the oral Alzheimer's disease treatment 'AR1001' (study name 'Polaris-AD').

The presentation will be led by Professor Sharon Sha of Stanford University, the global principal investigator of the AR1001 Phase 3 clinical trial. Dr. Sharon Sha, a professor of neurology and neuroscience clinical studies, is recognized as a world-renowned expert in brain neuroscience. She currently serves as the head of the Stanford Memory Disorders Center, vice chair of clinical research, and co-leader of the clinical and behavioral neurology research committee at the Stanford Alzheimer's Research Center.

At this conference, the company will present research findings showing that the analysis of pTau-217, a major biomarker of Alzheimer's, is excellent in determining the positive or negative status of the toxic protein 'amyloid beta.' Using the blood biomarkers pTau-217 and the amyloid beta 42 ratio can reduce the need for positron emission tomography (PET) and cerebrospinal fluid (CSF) tests, thereby saving time and costs in clinical trial screening.

Previously, at last year's CTAD, David Grilly, Aribio's Chief Medical Officer (CMO), introduced that through Phase 2 clinical trials, the effect of AR1001 was more pronounced in patients with high blood pTau-181 levels.

An Aribio representative stated, "Currently, various populations are being enrolled at Phase 3 clinical sites in the United States, the United Kingdom, the European Union, and Korea. The diversity of subjects is a very important factor when the U.S. Food and Drug Administration (FDA) approves new drugs, and we will strive to proceed with Phase 3 clinical trials without any setbacks."

Meanwhile, Aribio is in the process of a merger absorption with Solux. After the merger, the surviving company will be Solux, and the dissolved company and the post-merger name will be Aribio.

This content was produced with the assistance of AI translation services.